Spruce Biosciences, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Spruce Biosciences, Inc. (SPRB) had Deferred Tax Assets, Operating Loss Carryforwards of $44.72 million as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-09
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $44.72M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $35.48M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $33.40M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $33.87M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $44.72M 10-K · filed 2026-03-09 |
| 2024-12-31 | $35.48M 10-K · filed 2026-03-09 |
| 2023-12-31 | $33.40M 10-K · filed 2025-04-15 |
| 2022-12-31 | $33.87M 10-K · filed 2024-03-18 |
| 2021-12-31 | $27.57M 10-K · filed 2023-03-16 |
| 2020-12-31 | $16.38M 10-K · filed 2022-03-14 |
| 2019-12-31 | $6.26M 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |